Overview
Magnetic Resonance Imaging for the Early Detection of CNS Metastases in Women With Stage IV Breast Cancer
Status:
Unknown status
Unknown status
Trial end date:
1969-12-31
1969-12-31
Target enrollment:
0
0
Participant gender:
Female
Female
Summary
RATIONALE: Diagnostic procedures, such as magnetic resonance imaging (MRI), may help doctors find CNS metastases and plan treatment. PURPOSE: This randomized clinical trial is studying how well MRI finds CNS metastases in women with stage IV breast cancer.Phase:
N/AAccepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Jules Bordet InstituteTreatments:
Trastuzumab
Criteria
DISEASE CHARACTERISTICS:- Histologically confirmed breast cancer
- Stage IV disease
- HER2/neu-overexpression (3+ by immunohistochemistry AND/OR gene amplification by
fluorescence in situ hybridization)
- Undergoing treatment with trastuzumab (Herceptin®) (alone or together with
chemotherapy) once weekly or 3 times weekly AND has achieved responding or stable
disease for ≥ 12 weeks
- No CNS metastases (i.e., brain parenchymal lesions and/or leptomeningeal
carcinomatosis)
- No uncontrolled metastatic disease at study entry
- Hormone receptor status
- Not specified
PATIENT CHARACTERISTICS:
- Female
- Menopausal status not specified
- Karnofsky performance status 70-100%
- No contraindication to MRI scan
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics